[PDF][PDF] Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent …
RS Herbst, VJ O'Neill, L Fehrenbacher… - Journal of Clinical …, 2007 - academia.edu
Journal of Clinical Oncology, 2007•academia.edu
Purpose Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal
antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor
tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit in the treatment
of non–small-cell lung cancer (NSCLC). A single-arm phase I and II study of bevacizumab
plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile.
antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor
tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit in the treatment
of non–small-cell lung cancer (NSCLC). A single-arm phase I and II study of bevacizumab
plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile.
Purpose
Bevacizumab, a humanized anti–vascular endothelial growth factor monoclonal antibody, and erlotinib, a reversible, orally available epidermal growth factor receptor tyrosine kinase inhibitor, have demonstrated evidence of a survival benefit in the treatment of non–small-cell lung cancer (NSCLC). A single-arm phase I and II study of bevacizumab plus erlotinib demonstrated encouraging efficacy, with a favorable safety profile.
academia.edu